Win-win for both animal and human patients

Could you provide a brief overview of your project – what are the main objectives and expected outcomes?

“Our project investigates the use of the novel MTH1 inhibitor OXC-101 (Karonudib) in dogs diagnosed with malignant lymphoma (either treatment-naïve or relapsed) and hemangiosarcoma post-splenectomy. The treatment is administered orally for three months, with both safety and efficacy continuously evaluated. The primary aim is to establish a safe and effective dosing strategy in veterinary patients, while also assessing measurable tumor responses.”

“Early clinical results are highly encouraging: several dogs have shown measurable tumor regression with minimal to no side effects. This is particularly promising, as there are currently no licensed veterinary treatments specifically for these cancer types, despite their poor prognosis and significant impact on canine welfare. The study has been approved by the appropriate ethical review board, and participation requires that the dog owner provides written informed consent.”

How does the research relate to the One Health concept? 

“This work exemplifies the comparative oncology approach within One Health. The project is conducted in collaboration with Professor Thomas Helleday’s group at Karolinska Institutet, where a parallel human clinical cancer research program is ongoing for OXC-101. Spontaneously arising cancers in dogs share many biological, genetic, and clinical similarities with human cancers, providing a unique and highly relevant translational model.”

“Importantly, the majority (96–97%) of new cancer drug development projects fail during clinical translation from preclinical models to human patients. Conventional laboratory models often fail to predict true clinical efficacy. By studying naturally occurring cancers in dogs ‒ who are already patients in need of better care ‒ we gain critical insights into treatment responses in an immune-competent host with tumor biology closely mirroring that of human cancers. This has the potential to accelerate successful drug development that benefits both animal and human patients.”

What do you consider the key challenges and opportunities in your research area in relation to comparative medicine and One Health?

“One of the main challenges in comparative oncology is designing trials that meet rigorous scientific and ethical standards while being feasible for pet owners and their animals. Recruiting suitable patients, ensuring consistent follow-up, and balancing data collection with animal welfare are essential considerations.”

“The opportunities, however, are substantial. This research offers: 

• The chance to provide new hope and improved quality of life for dogs with cancers that currently have limited or no effective treatments.
• A pathway to generate robust translational data that may guide human oncology drug development.
• A strengthened collaborative bridge between veterinary and human medicine, advancing the One Health agenda.
• By aligning the needs of veterinary patients with the quest for better human cancer therapies, this project is a true win-win for both species.”